Featured Research

from universities, journals, and other organizations

Antiviral therapy may prevent liver cancer in hepatitis B patients

Date:
June 9, 2014
Source:
Henry Ford Health System
Summary:
Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma. "The results of this study allow us to reassure our patients that we are not just treating their viral levels, but that antiviral therapy may actually lessen their chance of developing liver cancer," said the study's lead investigator.

Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma (HCC).

That was the finding of a study published in the May issue of Clinical Gastroenterology and Hepatology. Investigators from Henry Ford Health System in Detroit, Geisinger Health System in Danville, Pa., and Kaiser Permanente in Honolulu, Hawaii and Portland, Ore. participated in the study, along with investigators from the Centers for Disease Control and Prevention in Atlanta.

According to the first-of-its-kind analysis of more than 2,600 adult participants with hepatitis B, those treated with antiviral therapy had a significantly lower occurrence of HCC during a five-year follow up period. Overall, 3 percent of patients developed HCC during the study's timeframe. But patients who received antiviral therapy were 60 percent less likely to develop HCC than untreated patients.

"The results of this study allow us to reassure our patients that we are not just treating their viral levels, but that antiviral therapy may actually lessen their chance of developing liver cancer," said the study's lead investigator, Henry Ford Health System's Stuart C. Gordon, M.D., who worked closely with Henry Ford Senior Scientist Mei Lu in Detroit.

HCC accounts for the most liver cancers in the United States, typically occurs in people age 50 or older and is more common in men. If the cancer cannot be removed, it is usually fatal in three to six months. In most cases, HCC is caused by scarring in the liver -- cirrhosis -- which can be a result of alcohol abuse, hepatitis B or C, chronic inflammation of the liver or an iron overload.

"This study was one of the first to address antiviral therapy and its efficacy in preventing hepatitis B from developing into liver cancer," said Joseph Boscarino, Ph.D., senior scientist and investigator for the Geisinger site. "With this information, clinicians can begin to prescribe antiviral therapy for hepatitis B patients with the goal of preventing a common and dangerous form of cancer."


Story Source:

The above story is based on materials provided by Henry Ford Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. Stuart C. Gordon, Lois E. Lamerato, Loralee B. Rupp, Jia Li, Scott D. Holmberg, Anne C. Moorman, Philip R. Spradling, Eyasu H. Teshale, Vinutha Vijayadeva, Joseph A. Boscarino, Emily M. Henkle, Nancy Oja–Tebbe, Mei Lu. Antiviral Therapy for Chronic Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma in a US Population. Clinical Gastroenterology and Hepatology, 2014; 12 (5): 885 DOI: 10.1016/j.cgh.2013.09.062

Cite This Page:

Henry Ford Health System. "Antiviral therapy may prevent liver cancer in hepatitis B patients." ScienceDaily. ScienceDaily, 9 June 2014. <www.sciencedaily.com/releases/2014/06/140609153516.htm>.
Henry Ford Health System. (2014, June 9). Antiviral therapy may prevent liver cancer in hepatitis B patients. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/06/140609153516.htm
Henry Ford Health System. "Antiviral therapy may prevent liver cancer in hepatitis B patients." ScienceDaily. www.sciencedaily.com/releases/2014/06/140609153516.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins